These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32522498)

  • 1. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy.
    Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL
    Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy.
    Wojciechowski J; Purohit VS; Harnisch LO; Dua P; Tan B; Nicholas T
    Clin Pharmacol Ther; 2022 Dec; 112(6):1291-1302. PubMed ID: 36104012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.
    Sherlock SP; Palmer J; Wagner KR; Abdel-Hamid HZ; Bertini E; Tian C; Mah JK; Kostera-Pruszczyk A; Muntoni F; Guglieri M; Brandsema JF; Mercuri E; Butterfield RJ; McDonald CM; Charnas L; Marraffino S
    J Neurol; 2022 Aug; 269(8):4421-4435. PubMed ID: 35396602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab in fukutin-related protein limb-girdle muscular dystrophy.
    Leung DG; Bocchieri AE; Ahlawat S; Jacobs MA; Parekh VS; Braverman V; Summerton K; Mansour J; Stinson N; Bibat G; Morris C; Marraffino S; Wagner KR
    Muscle Nerve; 2021 Aug; 64(2):172-179. PubMed ID: 33961310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients With Duchenne Muscular Disease.
    Bhattacharya I; Manukyan Z; Chan P; Heatherington A; Harnisch L
    J Clin Pharmacol; 2018 Mar; 58(3):314-326. PubMed ID: 29023829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy.
    Sherlock SP; Palmer J; Wagner KR; Abdel-Hamid HZ; Tian C; Mah JK; Muntoni F; Guglieri M; Butterfield RJ; Charnas L; Marraffino S
    Sci Rep; 2022 Nov; 12(1):18762. PubMed ID: 36335191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
    Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
    Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
    Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects.
    Bhattacharya I; Pawlak S; Marraffino S; Christensen J; Sherlock SP; Alvey C; Morris C; Arkin S; Binks M
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):484-497. PubMed ID: 28881472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.
    Sherlock SP; Zhang Y; Binks M; Marraffino S
    Biomark Med; 2021 Jun; 15(10):761-773. PubMed ID: 34155911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial.
    Muntoni F; Guglieri M; Mah JK; Wagner KR; Brandsema JF; Butterfield RJ; McDonald CM; Mayhew AG; Palmer JP; Marraffino S; Charnas L; Mercuri E
    PLoS One; 2022; 17(8):e0272858. PubMed ID: 35998119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration.
    Goemans N; Wong B; Van den Hauwe M; Signorovitch J; Sajeev G; Cox D; Landry J; Jenkins M; Dieye I; Yao Z; Hossain I; Ward SJ;
    PLoS One; 2020; 15(6):e0232870. PubMed ID: 32555695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial.
    Wagner KR; Guglieri M; Ramaiah SK; Charnas L; Marraffino S; Binks M; Vaidya VS; Palmer J; Goldstein R; Muntoni F
    Biomark Med; 2021 Oct; 15(15):1389-1396. PubMed ID: 34533053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.